Historical Stock Chart
2 Months : From Sep 2019 to Nov 2019
Jennifer Wilson Recognized as a Finalist for Female Executive of the Year
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that Jennifer Wilson, Vice President of Business Development, has been named a Finalist in the Female Executive of the Year – Business Products category in the 16th annual Stevie® Awards for Women in Business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005098/en/
Jennifer Wilson VP of Business Development, TXMD. (Photo: Business Wire)
The Stevie Awards for Women in Business honor women executives, entrepreneurs, employees and the companies they run – worldwide. The Stevie Awards have been hailed as the world’s premier business awards.
Finalists were determined by the average scores of more than 150 business professionals around the world, working on seven juries. Their scores will also determine the Gold, Silver, and Bronze Stevie Award placements that will be revealed at the 16th annual awards dinner and presentations in New York.
“We are incredibly proud of the contributions Jennifer has made to TherapeuticsMD which has led to continued business growth and increased awareness for our products,” said TherapeuticsMD Co-Founder and Chief Executive Officer Robert Finizio. “We congratulate Jennifer and believe that she will play an integral role in furthering our mission to empower women with innovative solutions that address previously unmet needs at every phase of their life.”
“In its sixteenth year, the Stevie Awards for Women in Business received a record number of nominations. With the second annual Women|Future Conference preceding the announcement of winners on Nov. 15, it will be a day to celebrate the achievements of working women around the world,” said Michael Gallagher, founder and Executive Chairman of the Stevie Awards. “We’re looking forward to recognizing the Stevie Award winners next month.”
This year’s Stevie Awards for Women in Business event will be complemented by a two-day educational and networking conference called the Women|Future Conference, also at the Marriott Marquis Hotel on November 14-15, 2019.
Details about the Stevie Awards for Women in Business and the list of Finalists in all categories are available at www.StevieAwards.com/Women.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.
This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA™, BIJUVA® and its hormone therapy drug candidates and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191010005098/en/
Vice President Investor Relations
561-961-1900, ext. 2088